Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Women's Health Issues
AARP Public Policy Institute. (2010). Health Care Reform Legislation Closes the Medicare Part D coverage gap. Available: http://assets.aarp.org/rgcenter/ppi/health-care/fs182-doughnut-hole-reform.pdf. Accessed June 10, 2013.
- Current treatment approaches for Paget's disease of the bone.Discovery Medicine. 2010; 10: 209-212
- Health economics of osteoporosis.Best Practices & Research Clinical Endocrinology & Metabolism. 2008; 22: 885-900
- Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.American Journal of Medicine. 2007; 120: 251-256
Centers for Medicare and Medicaid Services (CMS). (2011). Medicare prescription drug benefit manual chapter 13: Premium and cost-sharing subsidies for low-income individuals. Available: http://www.cms.gov/Regulations-and Guidance/Guidance/Transmittals/Downloads/Chapter13.pdf. Accessed June 6, 2013.
- Estimated prevalence and patterns of presumed osteoporosis among older Americans based on Medicare data.Osteoporosis International. 2009; 20: 1507-1515
- Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.American Journal of Geriatric Pharmacotherapy. 2011; 9: 241-249
- More accurate racial and ethnic codes for Medicare administrative data.Health Care Financing Review. 2008; 29: 27
- Falling into the coverage gap: Part D drug costs and adherence for Medicare advantage prescription drug plan beneficiaries with diabetes.Health Services Research. 2010; 45: 355-375
- Differences in outcome between black and white elderly hip fracture patients.Journal of Chronic Diseases. 1987; 40: 931-938
- Pharmacy benefits and the use of drugs by the chronically ill.JAMA. 2004; 291: 2344-2350
- Prescription drug cost sharing: Associations with medication and medical utilization and spending and health.JAMA. 2007; 298: 61-69
- Part D coverage gap and adherence to diabetes medications.American Journal of Managed Care. 2010; 16: 911-918
Hagen, G., Wisløff, T., Falch, J., Lofthus, C., Frihagen, F., Wensaas, K.-A., et al. (2011). Efficacy and cost-effectiveness of alendronate for the prevention of fractures in postmenopausal women in Norway. Report from Norwegian Knowledge Centre for the Health Services. No 10–2011.
- How the doughnut hole affects prescription fulfillment decisions involving cardiovascular medications for Medicare Part D enrollees.Managed Care. 2010; 19: 36-44
- The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.Journal of Managed Care Pharmacy. 2011; 17: 25-39
- Osteoporosis healthcare disparities in postmenopausal women.Journal of Women's Health. 2012; 21: 1232-1236
- The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization.Medical Care. 1990; 28: 907-917
- Interventions to improve osteoporosis medication adherence and persistence: A systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group.Osteoporosis International. 2013; 24: 2907-2918
Hoadley, J., Hargrave, E., Merrell, K., Cubanski, J., & Neuman, T. (2007). Medicare Part D 2008 data spotlight: Benefit design. Available: http://www.kff.org/medicare/upload/7713.pdf. Accessed July 26, 2012.
Hoadley, J., Hargrave, E., Merrell, K., Cubanski, J., & Neuman, T. (2008). Medicare Part D 2008 data spotlight: formularies. Available: http://www.kff.org/medicare/upload/7734.pdf. Accessed July 26, 2012.
Hoadley, J., Cubanski, J., Hargrave, E., Summer, L., & Neuman, T. (2009). Part D plan availability in 2010 and key changes since 2006. Available: http://www.kff.org/medicare/upload/7986.pdf. Accessed July 26, 2012.
- Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs.JAMA. 2008; 299: 1929-1936
- Race and sex differences in mortality following fracture of the hip.American Journal of Public Health. 1992; 82: 1147-1150
- Employer drug benefit plans and spending on prescription drugs.JAMA. 2002; 288: 1733-1739
- Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis.Health Services Research. 2010; 45: 1227-1250
- Association of Medicare Part D medication out-of-pocket costs with utilization of statin medications.Health Services Research. 2012; 48 (12/2012b): 1311-1313https://doi.org/10.1111/1475-6773.12022
- Out-of-pocket medication costs, and the use of medications and health care services among children with asthma.JAMA. 2012; 307: 1284-1291
- Fracture reduction affects Medicare economics (FRAME): Impact of increased osteoporosis diagnosis and treatment.Osteoporosis International. 2005; 16: 1545-1557
- The impact of Medicare Part D on prescription drug use by the elderly.Health Affairs. 2007; 26: 1735-1744
- Insurance coverage for prescription drugs: Effects on use and expenditures in the Medicare population.Medical Care. 1999; 37: 926-936
- Compliance with drug therapies for the treatment and prevention of osteoporosis.Maturitas. 2004; 48: 271-287
Medpac. (2008). Report to the Congress: Medicare payment policy. Available: http://www.medpac.gov/chapters/Mar08_Ch05.pdf. Accessed April 1, 2013.
- Racial disparities in osteoporosis prevention in a managed care population.Southern Medical Journal. 2003; 96: 445-451
- America's bone health: The state of osteoporosis and low bone mass in our nation.Author, Washington, DC2002
National Osteoporosis Foundation. (2013). Clinician's guide to prevention and treatment of osteoporosis. Available: http://nof.org/files/nof/public/content/resource/913/files/580.pdf. Accessed January 2014.
- Poverty is a risk factor for osteoporosis fractures.Osteoporosis International. 2009; 20: 393-398
- Cost-effectiveness strategies to treat osteoporosis in elderly women.Southern Medical Journal. 2006; 99: 123-131
- Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: A clinical practice guideline from the American college of physicians.Annals of Internal Medicine. 2008; 149: 404-415
- Effects of reaching the drug benefit threshold on Medicare members' healthcare utilization during the first year of Medicare Part D.Medical Care. 2008; 46: 1116-1122
Rosen, H. N. (2013). Bisphosphonates in the management of osteoporosis in postmenopausal women. In: UpToDate, Basow, D. S. (Ed.). UpToDate, Waltham, MA. Available from: http://www.uptodate.com/home/help-manual-citing.
- The effects of copayments and generic substitution on the use and costs of prescription drugs.Inquiry. 1993; 30: 189-198
- Compliance with osteoporosis medications.Archives of Internal Medicine. 2005; 165: 2414-2419
- Stata Statistical Software: Release 12.Author, College Station, TX2011
- Therapies for treatment of osteoporosis in US women: Cost-effectiveness and budget impact considerations.American Journal of Managed Care. 2008; 14: 605-615
United States General Accountability Office. (2007). Medicare Part D low-income subsidy. Available: http://www.gao.gov/new.items/d07555.pdf. Accessed April 1, 2013.
U.S. Department of Health and Human Services. (2012). Medicare beneficiary savings and the Affordable Care Act. Available: http://www.healthcare.gov/news/reports/affordablecareact.html. Accessed June 10, 2013.
- Compliance with drug therapy for postmenopausal osteoporosis.Osteoporosis International. 2006; 17: 1645-1652
- The validity of race and ethnicity in enrollment data for Medicare beneficiaries.Health Services Research. 2012; 47: 1300-1321
- The effects of the coverage gap on drug spending: A closer look at Medicare Part D.Health Affairs (Millwood). 2009; 28: w317-w325
- Cost-effectiveness of the treatment and prevention of osteoporosis—A review of the literature and a reference model.Osteoporosis International. 2007; 18: 9-23
Funding Sources: This research was supported by a faculty development grant (AHC-FRD Grant 09.11) from the University of Minnesota Academic Health Center. Dr. Karaca-Mandic also had support from the National Institute on Aging (Grant 5K01AG036740). Funding was used for data purchase and research assistant support. The funding organization played no role in the conduct of this study.
Ethical approval: The study proposal was submitted to the Institutional Review Board (IRB) at the University of Minnesota reviewed the study. Because all data were de-identified, the study was exempted from human subjects review (proposal # 0912E75303).